Glucocorticoid sensitivity: pathology, mutations and clinical implications

References

• Kralli A, Bohen SP, Yamamoto KR. LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc. Natl Acad. Sci. USA92, 4701–4705 (1995).
   PubMed Web of Science ®Google Scholar
• Diaz-Borjon A, Richaud-Patin Y, Alvarado DLB, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine67, 40–48 (2000).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Walker EA, Bujalska IJ et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrinol. Rev.25, 831–866 (2004).
   PubMed Web of Science ®Google Scholar
• Seckl JR. 11β-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr. Opin. Pharmacol.4, 597–602 (2004).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes54, 1023–1031 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart PM. Tissue-specific Cushing’s syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol.149, 163–168 (2003).
   PubMed Web of Science ®Google Scholar
• Holmes MC, Sangra M, French KL. 11β-hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience137(3), 865–873 (2005).
   PubMed Web of Science ®Google Scholar
• Paterson JM, Seckl JR, Mullins JJ. Genetic manipulation of 11β-hydroxysteroid dehydrogenases in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.289, R642–R652 (2005).
   Web of Science ®Google Scholar
• Seckl JR, Yau J, Holmes M. 11β-hydroxysteroid dehydrogenases: a novel control of glucocorticoid action in the brain. Endocrinol. Res.28, 701–707 (2002).
   PubMed Web of Science ®Google Scholar
• Draper N, Stewart PM. 11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol.186, 251–271 (2005).
   PubMed Web of Science ®Google Scholar
• Lu NZ, Cidlowski JA. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann. NY Acad. Sci.1024, 102–123 (2004).
   PubMed Web of Science ®Google Scholar
• Yudt MR, Jewell CM, Bienstock RJ, Cidlowski JA. Molecular origins for the dominant negative function of human glucocorticoid receptor β. Mol. Cell Biol.23, 4319–4330 (2003).
   PubMed Web of Science ®Google Scholar
• Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev.17, 245–261 (1996).
   PubMed Web of Science ®Google Scholar
• Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol. Cell18, 331–342 (2005).
   PubMed Web of Science ®Google Scholar
• Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol. Metab.15, 418–424 (2004).
   PubMed Web of Science ®Google Scholar
• Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology142, 1371–1376 (2001).
   PubMed Web of Science ®Google Scholar
• Draper N, Echwald SM, Lavery GG. Association studies between microsatellite markers within the gene encoding human 11β-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J. Clin. Endocrinol. Metab.87, 4984–4990 (2002).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Yamamoto H, Kenyon CJ. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest.112, 83–90 (2003).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science294, 2166–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Alberts P, Nilsson C, Selen G et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology144, 4755–4762 (2003).
   PubMed Web of Science ®Google Scholar
• Alberts P, Engblom L, Edling N et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia45, 1528–1532 (2002).
   PubMed Web of Science ®Google Scholar
• Barf T, Vallgarda J, Emond R et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem.45, 3813–3815 (2002).
   PubMed Web of Science ®Google Scholar
• Chrousos GP. Is 11{β}-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc. Natl Acad. Sci. USA1011(17), 6329–6330 (2004).
   Google Scholar
• Draper N, Walker EA, Bujalska IJ et al. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genet.34, 434–439 (2003).
   PubMed Web of Science ®Google Scholar
• Lavery GG, Walker EA, Draper N et al. Hexose-6-phosphate dehydrogenase knockout mice lack 11β-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J. Biol. Chem.281(10), 6546–6551 (2006).
   PubMed Web of Science ®Google Scholar
• Galigniana MD, Housley PR, DeFranco DB, Pratt WB. Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton. J. Biol. Chem.274, 16222–16227 (1999).
   PubMed Web of Science ®Google Scholar
• Galigniana MD, Radanyi C, Renoir JM, Housley PR, Pratt WB. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem.276, 14884–14889 (2001).
   PubMed Web of Science ®Google Scholar
• Guo Y, Guettouche T, Fenna M et al. Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J. Biol. Chem.276, 45791–45799 (2001).
   PubMed Web of Science ®Google Scholar
• Murphy PJ, Kanelakis KC, Galigniana MD, Morishima Y, Pratt WB. Stoichiometry, abundance, and functional significance of the hsp90/hsp70-based multiprotein chaperone machinery in reticulocyte lysate. J. Biol. Chem.276, 30092–30098 (2001).
   PubMed Web of Science ®Google Scholar
• Elbi C, Walker DA, Romero G et al. Molecular chaperones function as steroid receptor nuclear mobility factors. Proc. Natl Acad. Sci. USA101, 2876–2881 (2004).
   PubMed Web of Science ®Google Scholar
• Hager GL, Lim CS, Elbi C, Baumann CT. Trafficking of nuclear receptors in living cells. J. Steroid Biochem. Mol. Biol.74, 249–254 (2000).
   PubMed Web of Science ®Google Scholar
• Hager GL. The dynamics of intranuclear movement and chromatin remodeling by the glucocorticoid receptor. Ernst Schering Res. Found. Workshop40, 111–129 (2002).
   Google Scholar
• Stavreva DA, Muller WG, Hager GL, Smith CL, McNally JG. Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol. Cell Biol.24, 2682–2697 (2004).
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Wang JC, Derynck MK. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl Acad. Sci. USA100, 13845–13850 (2003).
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc. Natl Acad. Sci. USA99, 16701–16706 (2002).
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Zarember KA, Yamamoto KR. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J.20, 6071–6083 (2001).
   PubMed Web of Science ®Google Scholar
• Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl Acad. Sci. USA101, 15603–15608 (2004).
   PubMed Web of Science ®Google Scholar
• Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR. Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol. Endocrinol.1, 68–74 (1987).
   PubMedGoogle Scholar
• Alourfi Z, Donn RP, Stevens A, Berry A, McMaster A, Ray DW. Glucocorticoids suppress macrophage migration inhibitory factor (MIF) expression in a cell-type-specific manner. J. Mol. Endocrinol.34, 583–595 (2005).
   PubMed Web of Science ®Google Scholar
• Ray DW, Davis JR, White A, Clark AJ. Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells. Cancer Res.56, 3276–3280 (1996).
   PubMed Web of Science ®Google Scholar
• Baumann CT, Ma H, Wolford R et al. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol. Endocrinol.15, 485–500 (2001).
   PubMedGoogle Scholar
• Becker M, Baumann C, John S et al. Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Rep.3, 1188–1194 (2002).
   PubMed Web of Science ®Google Scholar
• Abruzzese RV, Godin D, Mehta V et al. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol. Ther.2, 276–287 (2000).
   PubMed Web of Science ®Google Scholar
• Han SJ, Demayo FJ, Xu J, Tsai SY, Tsai MJ, O’Malley BW. Steroid receptor coactivators SRC-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol. Endocrinol.20(1), 45–55 (2005).
   PubMedGoogle Scholar
• Jung SY, Malovannaya A, Wei J, O’Malley BW, Qin J. Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes. Mol. Endocrinol.19, 2451–2465 (2005).
   PubMedGoogle Scholar
• Nawaz Z, O’Malley BW. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol. Endocrinol.18, 493–499 (2004).
   PubMed Web of Science ®Google Scholar
• O’Malley BW. A life-long search for the molecular pathways of steroid hormone action. Mol. Endocrinol.19, 1402–1411 (2005).
   PubMed Web of Science ®Google Scholar
• Wu RC, Smith CL, O’Malley BW. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev.26, 393–399 (2005).
   PubMed Web of Science ®Google Scholar
• Cheskis BJ, McKenna NJ, Wong CW et al. Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. J. Biol. Chem.278, 13271–13277 (2003).
   PubMed Web of Science ®Google Scholar
• Lonard DM, Tsai SY, O’Malley BW. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol. Cell Biol.24, 14–24 (2004).
   PubMed Web of Science ®Google Scholar
• Garside H, Stevens A, Farrow S et al. Glucocorticoid ligands specify different interactions with NF-κB by allosteric effects on the glucocorticoid receptor DNA binding domain. J. Biol. Chem.279, 50050–50059 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens A, Garside H, Berry A, Waters C, White A, Ray D. Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: the role of tyrosine 735. Mol. Endocrinol.17, 845–859 (2003).
   PubMedGoogle Scholar
• Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW, Xu J. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res.6, 7993–8002 (2005).
   Google Scholar
• O’Malley BW. Results of a search for the mechanisms of steroid receptor regulation of gene expression. Ann. NY Acad. Sci.1038, 80–87 (2004).
   PubMed Web of Science ®Google Scholar
• Wu HY, Hamamori Y, Xu J et al. Nuclear hormone receptor coregulator GRIP1 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD. J. Biol. Chem.280, 3129–3137 (2005).
   PubMed Web of Science ®Google Scholar
• Ying H, Furuya F, Willingham MC, Xu J, O’Malley BW, Cheng SY. Dual functions of the steroid hormone receptor coactivator 3 in modulating resistance to thyroid hormone. Mol. Cell Biol.25, 7687–7695 (2005).
   PubMed Web of Science ®Google Scholar
• Ismaili N, Garabedian MJ. Modulation of glucocorticoid receptor function via phosphorylation. Ann. NY Acad. Sci.1024, 86–101 (2004).
   PubMed Web of Science ®Google Scholar
• Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol. Cell Biol.17, 3947–3954 (1997).
   PubMed Web of Science ®Google Scholar
• Szatmary Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J. Biol. Chem.279, 43708–43715 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Z, Garabedian MJ. Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27Kip1. J. Biol. Chem.278, 50897–50901 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Z, Frederick J, Garabedian MJ. Deciphering the phosphorylation “code” of the glucocorticoid receptor in vivo.J. Biol. Chem.277, 26573–26580 (2002).
   PubMed Web of Science ®Google Scholar
• Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev.14, 2314–2329 (2000).
   PubMed Web of Science ®Google Scholar
• Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J. Steroid Biochem. Mol. Biol.69, 195–204 (1999).
   PubMed Web of Science ®Google Scholar
• Groner B. Transcription factor regulation in mammary epithelial cells. Domest. Anim. Endocrinol.23, 25–32 (2002).
   PubMed Web of Science ®Google Scholar
• Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. Mol. Endocrinol.15, 1062–1076 (2001).
   PubMedGoogle Scholar
• Goleva E, Kisich KO, Leung DY. A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J. Immunol.169, 5934–5940 (2002).
   PubMed Web of Science ®Google Scholar
• Biola A, Andreau K, David M et al. The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes. FEBS Lett.487, 229–233 (2000).
   PubMed Web of Science ®Google Scholar
• Nelson G, Wilde GJ, Spiller DG et al. NF-κB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J. Cell Sci.116, 2495–2503 (2003).
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Russcher H, Lamberts SW. Genetic polymorphisms and multifactorial diseases: facts and fallacies revealed by the glucocorticoid receptor gene. Trends Endocrinol. Metab.16, 445–450 (2005).
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Feelders RA, van den Beld AW et al. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am. J. Med.117, 158–162 (2004).
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res.59, 333–357 (2004).
   PubMedGoogle Scholar
• de Lange P, Koper JW, Huizenga NA et al. Differential hormone-dependent transcriptional activation and -repression by naturally occurring human glucocorticoid receptor variants. Mol. Endocrinol.11, 1156–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Huizenga NA, Koper JW, de Lange P et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab.83, 144–151 (1998).
   PubMed Web of Science ®Google Scholar
• Lin RC, Wang XL, Dalziel B, Caterson ID, Morris BJ. Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes. Res.11, 802–808 (2003).
   PubMedGoogle Scholar
• Lin RC, Wang XL, Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension41, 404–407 (2003).
   PubMed Web of Science ®Google Scholar
• Rosmond R. Letter: glucocorticoid receptor N363S variant in obesity: comes into vanity and goes into darkness. Obes. Res.11, 1606–1607 (2003).
   PubMedGoogle Scholar
• Ukkola O, Rosmond R, Tremblay A, Bouchard C. Glucocorticoid receptor Bcl I variant is associated with an increased atherogenic profile in response to long-term overfeeding. Atherosclerosis157, 221–224 (2001).
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Koper JW, van den Beld AW et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin. Endocrinol. (Oxford)59, 585–592 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens A, Donn R, Ray D. Regulation of glucocorticoid receptor gamma (GRγ) by glucocorticoid receptor haplotype and glucocorticoid. Clin. Endocrinol. (Oxford)61, 327–331 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens A, Ray DW, Zeggini E et al. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J. Clin. Endocrinol. Metab.89, 892–897 (2004).
   PubMed Web of Science ®Google Scholar
• Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP. Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J. Clin. Endocrinol. Metab.89, 1939–1949 (2004).
   PubMed Web of Science ®Google Scholar
• Cleasby ME, Kelly PA, Walker BR, Seckl JR. Programming of rat muscle and fat metabolism by in utero overexposure to glucocorticoids. Endocrinology144, 999–1007 (2003).
   PubMed Web of Science ®Google Scholar
• Cleasby ME, Livingstone DE, Nyirenda MJ, Seckl JR, Walker BR. Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood? Eur. J. Endocrinol.148, 129–138 (2003).
   PubMed Web of Science ®Google Scholar
• Seckl JR, Meaney MJ. Glucocorticoid programming. Ann. NY Acad. Sci.1032, 63–84 (2004).
   PubMed Web of Science ®Google Scholar
• Seckl JR. Prenatal glucocorticoids and long-term programming. Eur. J. Endocrinol.151(Suppl. 3), U49–U62 (2004).
   PubMed Web of Science ®Google Scholar
• Weaver IC, Diorio J, Seckl JR, Szyf M, Meaney MJ. Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. Ann. NY Acad. Sci.1024, 182–212 (2004).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Bjornsdottir US, Halapi E et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc. Natl Acad. Sci. USA102, 14789–14794 (2005).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J.19, 182–191 (2002).
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between β-agonist and corticosteroid pathways. Hum. Mol. Genet.14, 1671–1677 (2005).
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Meazza C, Vivarelli M. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum.48, 1398–1407 (2003).
   PubMed Web of Science ®Google Scholar
• Donn R, Alourfi Z, Zeggini E et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum.50, 1604–1610 (2004).
   PubMed Web of Science ®Google Scholar
• Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J.15, 1110–1112 (2001).
   PubMedGoogle Scholar
• Kagoshima M, Wilcke T, Ito K et al. Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. Eur. J. Pharmacol.429, 327–334 (2001).
   PubMed Web of Science ®Google Scholar
• Norman M, Hearing SD. Glucocorticoid resistance – what is known? Curr. Opin. Pharmacol.2, 723–729 (2002).
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Hittelman AB, Pearce D, Garabedian MJ. Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol. Cell Biol.19, 5036–5049 (1999).
   PubMed Web of Science ®Google Scholar
• Herr I, Ucur E, Herzer K et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res.63, 3112–3120 (2003).
   PubMed Web of Science ®Google Scholar
• Gaitan D, DeBold CR, Turney MK, Zhou P, Orth DN, Kovacs WJ. Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer. Mol. Endocrinol.9, 1193–1201 (1995).
   PubMedGoogle Scholar
• Witschi H, Espiritu I, Ly M, Uyeminami D. The chemopreventive effects of orally administered dexamethasone in Strain A/J mice following cessation of smoke exposure. Inhal. Toxicol.17, 119–122 (2005).
   PubMed Web of Science ®Google Scholar
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol.27, 24–31 (2006).
   PubMed Web of Science ®Google Scholar
• Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-α plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry66, 41–48 (2005).
   PubMed Web of Science ®Google Scholar
• Griffin MG, Resick PA, Yehuda R. Enhanced cortisol suppression following dexamethasone administration in domestic violence survivors. Am. J. Psychiatry162, 1192–1199 (2005).
   PubMed Web of Science ®Google Scholar